发明名称 |
Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels |
摘要 |
The present invention provides a kit for the dietary management of cardiovascular patients with cardiovascular disease who are deficient in blood Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) levels, the kit including a diagnostic assay for determining blood levels of EPA, DHA and Docosapentaenoic acid (DPA) and a pharmaceutical grade prescription medical food omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of EPA, DPA and DHA in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA are about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition. The kit may further contain instructions for use of its components. |
申请公布号 |
US9119826(B2) |
申请公布日期 |
2015.09.01 |
申请号 |
US201213584428 |
申请日期 |
2012.08.13 |
申请人 |
Pivotal Therapeutics, Inc. |
发明人 |
Jackowski George;MacSweeney Rachelle;Shaikh Nisar;Yantha Jason;Schini-Kerth Valerie |
分类号 |
A61K31/202;A61K31/685;A61P9/00;A61K31/232;A61K45/06 |
主分类号 |
A61K31/202 |
代理机构 |
Ferris H. Lander, Inc. |
代理人 |
Ferris H. Lander, Inc. |
主权项 |
1. A pharmaceutical grade formulation consisting of eicopentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA) wherein ratio of EPA:DHA is in the range of 5.7:1-6.3:1, the amount of EPA+DHA in the formulation is about 82.62% to about 87.82% by weight of the total fatty acid content of the formulation, and about 88.26% to about 93.06% by weight of the total omega-3 content of the formulation; the formulation contains from about 93.15% to about 94.87% by weight omega-3 fatty acids; the sum of EPA, DHA, DPA is from about 85.72% to about 87.82% by weight of the total fatty acids in the formulation, and from about 91.38% to about 95.94% by weight of the total omega-3 present in the formulation; said formulation contains about 2.53% to about 3.13% by weight of the total fatty acids in the formulation of DPA, about 3.04% to about 3.48% by weight of the total fatty acids in the formulation of arachidonic acid (AA), and about 3.21% to about 3.45% by weight of the total fatty acids in the formulation, of omega-3 fatty acids having 18 carbons, wherein said 18 carbon atom omega-3 fatty acids are alpha-linolenic acid (ALA) and stearidonic acid (SDA); and wherein the sum of ALA and SDA is about 3.40% to about 3.68 by weight of the total omega-3 present in the formulation. |
地址 |
Ontario CA |